HYBRIDOMA DEVELOPMENT SERVICES

Hybridoma technology is the cornerstone of our custom hybridoma monoclonal antibody services, creating cell lines that produce monoclonal antibodies with unmatched specificity. This method is essential for advancing research, diagnostics, and therapeutic solutions, offering antibodies with superior stability and affinity.

Our hybridoma antibody production services are versatile, accommodating a wide range of antigens, from peptides to eukaryotic cells. Through peptide synthesis and DNA immunization, we tailor our approach to each project, ensuring optimal antigen presentation and immune response.

Quality is paramount in our hybridoma monoclonal antibody production services. We begin with a strategic immunization plan, using either in situ DNA or synthetic peptides as immunogens, to maintain antigen integrity and stimulate a targeted immune response, ensuring the production of high-affinity, biologically relevant antibodies.

Yes, our custom hybridoma development process yields antibodies suitable for a broad spectrum of applications. From diagnostic assays requiring high sensitivity to therapeutic interventions needing humanized antibodies as well as research tools critical for academic publications, we leverage our expertise to meet diverse application demands.

Our hybridoma production services stand out due to over 20 years of experience and a success rate exceeding 90%. We excel in managing complex projects, from antigen design to antibody production, ensuring each antibody meets our high standards of affinity and specificity.

The duration of our custom hybridoma generation process varies, but we aim for efficiency with positive clones available within 45 days, thanks to our fast-track protocol. The entire project typically spans 90-120 days, including time for thorough validation testing.

Our hybridoma development services yield antibodies ranging from 40 mg/l in serum-containing mediums to 20 mg/l in serum-free conditions. We guarantee antibodies of the highest purity (>95%), ensuring they’re suitable for various applications, including in vivo use.

We prioritize antigen design to ensure the development of biologically relevant antibodies. Our comprehensive evaluation phase allows for tailored immunization strategies and screening processes, ensuring the antibodies produced are perfectly aligned with your project’s goals.

Initial screening employs ELISA, complemented by flow cytometry and other assays to ensure antibodies meet application-specific requirements. This meticulous screening process guarantees our antibodies’ optimal performance across diagnostic and therapeutic applications.

Hybridoma technology offers several key benefits:

1. Unlimited antibody production: Hybridomas are theoretically immortal, allowing for long-term antibody production. However, their “immortality” can be affected by genetic drift and mutations, which may compromise stability and productivity over time. To ensure you never lose access to your antibody, we recommend using our antibody sequencing services. This is the most reliable solution to guarantee continuous antibody production in the long run. And if you no longer have access to the hybridoma itself, don’t worry—we can still retrieve your sequence from a purified antibody sample through our de novo antibody sequencing service.
2. Naturally high-affinity antibodies: Hybridomas are derived from B cells that have undergone in vivo affinity maturation, resulting in antibodies with naturally high affinity and specificity.
3. Antibodies with high developability: This method preserves the natural pairing of heavy and light variable chains (VH/VL pairing), which enhances antibody developability and ensures optimal performance for downstream applications.

Hybridomas are immortalized cell lines, key to our custom hybridoma development services, that produce monoclonal antibodies. Created by fusing B cells with myeloma cells, this method, pioneered by Georges Kohler and Cesar Milstein in 1975, utilizes electrofusion or polyethylene glycol (PEG) for the continuous production of high-quality antibodies.

Rodents, such as mice, rats, and hamsters, are the primary sources for our hybridoma monoclonal antibody production services due to their effective monohybridoma production. We also explore heterohybridomas from different species, including chickens, rabbits, or humans, to expand our antibody generation capabilities, despite their potential instability.

Our hybridoma production services cultivate hybridomas in suspension cultures, a humane method aligned with serum-free and chemically-defined mediums. This approach minimizes contamination and supports the production of high-purity antibody stocks, reflecting our commitment to ethical and efficient antibody production.

Hybridoma cell lines, central to our custom hybridoma generation process, are crucial for producing IgG monoclonal antibodies for diagnostics and research. These antibodies can be modified for specific antigen detection, and through hybridoma sequencing, we ensure their long-term productivity and adaptability for recombinant expression.

Hybridoma technology, foundational to our hybridoma antibody production services, enables the unlimited and reproducible creation of monoclonal antibodies. This cost-effective method is essential for generating antibodies with preserved natural heavy and light chain pairing, offering high stability and specificity for diagnostics and therapeutics.

To guarantee the specificity of antibodies, our hybridoma development services employ strategic immunization techniques. By preserving the antigen’s native structure through DNA immunization or recombinant expression, we ensure the generation of antibodies tailored for membrane-bound targets or specific epitopes, crucial for their intended diagnostic or therapeutic applications.

B cell activation is pivotal in our custom hybridoma development services for producing monoclonal antibodies. Mature B cells, activated in a T cell-dependent manner, are essential for generating antibodies with high specificity and affinity, significantly enhancing the quality and performance of hybridoma-produced antibodies.

T cell-dependent activation, a cornerstone of our hybridoma monoclonal antibody production services, involves the presentation of antigens to B cells alongside helper T cell involvement. This process, crucial for a strong immune response, fosters the production of high-affinity antibodies, underpinning successful hybridoma development.

Hybridoma-generated antibodies, central to our custom hybridoma generation process, excel in diagnostics, therapeutics, and research. Their high specificity and stability make them ideal for precise antigen detection in ELISA and flow cytometry, and they are pivotal in developing therapeutic antibodies for complex diseases.

While our hybridoma antibody production services yield highly specific antibodies, a single antibody may not meet all diagnostic criteria. The suitability of an antibody for a particular diagnostic application depends on its affinity, antigen nature, and assay conditions, necessitating tailored antibody selection.

Beyond their primary use in diagnostics and therapeutics, antibodies produced through our hybridoma production services find roles in basic research, protein interaction studies, and vaccine development. They’re also instrumental in bioengineering for antibody-drug conjugates and in agriculture for enhancing disease resistance.